AQST Stock Analysis: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$5.03
0.31 (6.57%)
▲
5d:
+19.19%
30d:
+18.91%
90d:
+27.99%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AQST is 13.3% above its trading range ($4.44). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AQST is 13.3% above its trading range ($4.44). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $5.03, which is considered extended relative to its 30-day fair value range of $3.92 to $4.44.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is approaching resistance at $5.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.89 (+76.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is approaching resistance at $5.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.89 (+76.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.92 -
$4.44
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+13.3% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 76.7% below Wall St target ($8.89)
Trading Range Analysis
30-Day Trading Range
$3.92 -
$4.44
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.87
Resistance Level
$5.11
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.18
Wall Street Target
$8.89
(+76.7%)
Revenue Growth (YoY)
65.7%
Profit Margin
-137.1%
Share & Embed Analysis
Last updated: June 23, 2026 10:11 PM ET
Data refreshes hourly during market hours. Next update: 11:11 PM
Data refreshes hourly during market hours. Next update: 11:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
A Ernest Toth Jr
SELL
58254 shares
2026-03-10
Cassie Jung
SELL
45791 shares
2026-03-10
Daniel Barber
SELL
180677 shares
2026-03-10
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
